Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525425 | 0.81 | DAO (0.48) | ALDH1A1KDM4EGAARAB9AKMT2A | |
| SCHEMBL28373483 | 0.77 | GSK3B (0.44) | GSK3BCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2872059 | 0.77 | GSK3B (0.67) | GSK3BCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21501020 | 0.74 | GSK3B (0.42) | GSK3BCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6420455 | 0.72 | DAO (0.44) | TSHRALDH1A1L3MBTL1KDM4EGLA | |
| SCHEMBL24573411 | 0.72 | SRD5A2 (0.47) | LMNATSHRALDH1A1MAPTCYP3A4 | |
| SCHEMBL21510688 | 0.72 | NPSR1 (0.49) | LMNATSHRALDH1A1L3MBTL1KDM4E | |
| SCHEMBL23013343 | 0.71 | DAO (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1356959 | 0.70 | LMNA (0.70) | GSK3BCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5714342 | 0.69 | CYP3A4 (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164967-A | EP2 and EP4 receptor antagonists | 武汉人福创新药物研发中心有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3114121-B1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9856244-B2 | Dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856244-B2 | Dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| EP-3114121-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | Bristol-Myers Squibb Company (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | DGAT2, MGAT2, DGAT1 | GSK3B 2030/4885CHRM2 3690/4885CHRM4 4535/4885 |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | DGAT2, DGAT1, MGAT2 | GSK3B 1856/4885CHRM2 4078/4885CHRM4 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.